【摘要】：原發(fā)性膽汁性膽管炎(PBC)是一種慢性肝內(nèi)膽汁淤積性疾病,患者膽汁分泌受阻,從而損害肝細(xì)胞,引發(fā)肝纖維化和肝硬化。目前PBC的患病率不斷升高,但約40%的患者對傳統(tǒng)治療藥物熊去氧膽酸(UDCA)并不敏感,導(dǎo)致疾病進(jìn)展風(fēng)險(xiǎn)升高。奧貝膽酸可有效治療對UDCA反應(yīng)不足或不耐受的患者,且治療耐受性良好。本文對PBC的流行病學(xué)、最新治療藥物奧貝膽酸的藥理學(xué)、毒理學(xué)以及臨床安全性和有效性進(jìn)行了概述。
[Abstract]:Primary biliary cholangitis (PBC) is a chronic intrahepatic cholestasis disease. The bile secretion of patients is blocked, which damages hepatocytes and leads to liver fibrosis and cirrhosis. At present, the prevalence of PBC is increasing, but about 40% of the patients are insensitive to the traditional drug ursodeoxycholic acid (UDCA), which leads to an increased risk of disease progression. Obercholic acid is effective in the treatment of patients who are insufficiently or intolerant to UDCA and are well tolerated. The epidemiology of PBC, pharmacology, toxicology, clinical safety and efficacy of the latest therapeutic drug Obercholic acid were reviewed.
【作者單位】： 江蘇奧賽康藥業(yè)股份有限公司;
【分類號】：R975

【相似文獻(xiàn)】

相關(guān)碩士學(xué)位論文 前1條

1 莫利英;他喹莫德和奧貝膽酸的合成研究[D];浙江工業(yè)大學(xué);2015年

，

本文編號：2324915